Prognostic factors and treatment outcomes in EGFR-mutated NSCLC with malignant pleural effusion: focus on intrathoracic chemotherapy and EGFR-TKI therapy.

Front Oncol · 2025 · PMC12500622 · PMID 41064085

Europe PMC DOI

hedged sentence

0.5900

closest p · 11.8× alpha

0.5900

boldest claim

The sentences

showed a trendP=0.59not close (p > 0.1)

In the cohort of 39 patients, EGFR-TKI monotherapy showed a trend toward longer MPE recurrence-free survival compared with the combination group (median 352 days vs. 298 days; P=0.59) ( 15 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.